JNJ · Earnings call · 2026Q3T · Full report

Immunology Competition Pressure

JOHNSON & JOHNSON · 2026-10-13 · Importance 43 · Surprise 32

STELARA declined 5.4% as biosimilar competition continued and patients shifted toward novel immunology classes. The pressure contrasts with Tremfya’s 68.2% growth, driven by IBD launch momentum and share gains in ulcerative colitis and Crohn’s disease. Management is positioning ICOTYDE as an oral therapy with biologic-like efficacy, placebo-like safety and once-daily convenience, while developing a guselkumab-golimumab combination for patients whose disease is not adequately controlled by monotherapy.

Key facts

• STELARA declined 5.4% reflecting continued competitive pressures from biosimilars and shift toward novel classes.